NasdaqCM:FBIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products.


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Fortress Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.4%

FBIO

-1.5%

US Biotechs

3.8%

US Market


1 Year Return

83.3%

FBIO

22.1%

US Biotechs

9.7%

US Market

Return vs Industry: FBIO exceeded the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: FBIO exceeded the US Market which returned 9.7% over the past year.


Shareholder returns

FBIOIndustryMarket
7 Day2.4%-1.5%3.8%
30 Day42.1%3.5%11.4%
90 Day48.5%9.0%6.8%
1 Year83.3%83.3%23.3%22.1%12.1%9.7%
3 Year-33.0%-33.0%26.1%22.1%36.2%27.2%
5 Year-3.9%-3.9%-5.5%-11.0%63.7%45.4%

Price Volatility Vs. Market

How volatile is Fortress Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fortress Biotech undervalued compared to its fair value and its price relative to the market?

6.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FBIO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: FBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FBIO is overvalued based on its PB Ratio (6.1x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Fortress Biotech forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

75.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: FBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FBIO's is expected to become profitable in the next 3 years.

Revenue vs Market: FBIO's revenue (37% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: FBIO's revenue (37% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Fortress Biotech performed over the past 5 years?

-6.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FBIO is currently unprofitable.

Growing Profit Margin: FBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FBIO is unprofitable, and losses have increased over the past 5 years at a rate of -6.8% per year.

Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: FBIO has a negative Return on Equity (-145.41%), as it is currently unprofitable.


Next Steps

Financial Health

How is Fortress Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: FBIO's short term assets ($158.8M) exceed its short term liabilities ($51.7M).

Long Term Liabilities: FBIO's short term assets ($158.8M) exceed its long term liabilities ($101.7M).


Debt to Equity History and Analysis

Debt Level: FBIO's debt to equity ratio (120.2%) is considered high.

Reducing Debt: FBIO's debt to equity ratio has increased from 39.9% to 120.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FBIO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 28.6% each year.


Next Steps

Dividend

What is Fortress Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.5yrs

Average management tenure


CEO

Lindsay Rosenwald (64yo)

6.5yrs

Tenure

US$1,090,016

Compensation

Dr. Lindsay Allan Rosenwald, M.D., serves as the Chairman of the Board of Directors at Avenue Therapeutics, Inc since February, 2015. He has been Executive Chairman, Chief Executive Officer and President o ...


CEO Compensation Analysis

Compensation vs Market: Lindsay's total compensation ($USD1.09M) is about average for companies of similar size in the US market ($USD1.30M).

Compensation vs Earnings: Lindsay's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Lindsay Rosenwald
Executive Chairman6.5yrsUS$1.09m12.02% $29.4m
Michael Weiss
Vice Chairman & Executive Vice Chairman of Strategic Development6.33yrsUS$1.09m12.37% $30.3m
Robyn Hunter
CFO, Treasurer & Corporate Secretary3yrsUS$1.80m0.12% $284.0k
George Avgerinos
Senior Vice President of Biologics Operations7yrsUS$386.35k0.79% $1.9m
Thomas Schaible
Project Leader of Inflammatory Bowel Disease7.08yrsno datano data

6.5yrs

Average Tenure

60.5yo

Average Age

Experienced Management: FBIO's management team is seasoned and experienced (6.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lindsay Rosenwald
Executive Chairman6.5yrsUS$1.09m12.02% $29.4m
Michael Weiss
Vice Chairman & Executive Vice Chairman of Strategic Development6.33yrsUS$1.09m12.37% $30.3m
Malcolm Hoenlein
Independent Director6.33yrsUS$78.00k0.10% $252.4k
Dov Klein
Independent Director4.92yrsUS$146.00k0.14% $346.9k
Eric Rowinsky
Co-Vice Chairman9.67yrsUS$278.50k0.79% $1.9m
J. Lobell
Independent Director14yrsUS$153.50k1.26% $3.1m
David Elliott
Scientific Advisor3yrsno datano data
Joel Weinstock
Scientific Advisor3yrsno datano data
Mark Lowdell
Member of Scientific Advisory Boardno datano datano data
Jimmie Harvey
Independent Director11.5yrsUS$133.50k0.061% $148.5k

6.3yrs

Average Tenure

63yo

Average Age

Experienced Board: FBIO's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.4%.


Top Shareholders

Company Information

Fortress Biotech, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fortress Biotech, Inc.
  • Ticker: FBIO
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$244.948m
  • Shares outstanding: 82.47m
  • Website: https://www.fortressbiotech.com

Number of Employees


Location

  • Fortress Biotech, Inc.
  • 2 Gansevoort Street
  • 9th Floor
  • New York
  • New York
  • 10014
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FBIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2011
CNBDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011
FBIO.PNasdaqCM (Nasdaq Capital Market)9.375% CUM PFD AUSUSDNov 2017

Biography

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 05:01
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.